Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: May 6, 2010

Premium

Dicerna Pharmaceuticals has named one of its co-founders, Douglas Fambrough, as its new CEO.

Fambrough will replace Jim Jensen, another Dicerna co-founder, who will remain on the company's board of directors and scientific advisory board.

Fambrough most recently served as general partner at Oxford Bioscience Partners, where he led the venture capital firm's investment in Sirna Therapeutics. Before joining Oxford, he was a researcher at the Whitehead/MIT Center for Genomic Research, now known as the Broad Institute.


Silence Therapeutics said it has promoted Jorg Kaufmann, its senior director of technologies, to the position of vice president of research.

Kaufmann holds a PhD in molecular biology from Philipps University Marburg.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.